pirenzepine has been researched along with Psychomotor Agitation in 22 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Psychomotor Agitation: A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This double-blind study investigated the efficacy and safety of rapid-acting intramuscular olanzapine in treating agitation associated with Alzheimer's disease and/or vascular dementia." | 9.10 | Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. ( Beasley, CM; Beckett, LM; Breier, A; David, SR; Feldman, PD; Jones, B; Meehan, KM; Mintzer, JE; Nisivoccia, JR; Wang, H, 2002) |
| "An intramuscular (IM) formulation of olanzapine has been developed because there are no rapid-acting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia." | 9.10 | A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. ( Birkett, M; Breier, A; Brook, S; David, S; Dossenbach, M; Ferchland, I; Kiesler, G; Meehan, K; Palmer, R; Sutton, V; Taylor, CC; Wright, P, 2002) |
| "The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia." | 9.09 | Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. ( Alaka, KJ; Bernardo, M; Birkett, M; Bradley, P; Breier, A; David, SR; Ferchland, I; Krueger, J; Meehan, K; Reinstein, M; San, L; Saunders, JC; Wright, P, 2001) |
| "This first clinical study of olanzapine in Japanese patients with schizophrenia was conducted to investigate the efficacy and safety of olanzapine." | 9.09 | Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan. ( Ishigooka, J; Miura, S; Murasaki, M, 2001) |
| " This resistant case of lethal catatonia responded selectively to high-dose olanzapine treatment." | 7.71 | Lethal catatonia responding to high-dose olanzapine therapy. ( Cassidy, EM; Finucane, J; O'Brien, M; O'Keane, V; Osman, MF, 2001) |
| "In olanzapine-treated patients, improvement in BPRS agitation and positive symptom scores was significantly greater at weeks 4, 5, and 6 (agitation scores, p < or = ." | 6.70 | Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. ( Hill, AL; Kinon, BJ; Milton, DR; Roychowdhury, SM, 2001) |
| " In 3 double-blind studies, acutely agitated patients with schizophrenia (N = 311), bipolar mania (N = 201), or dementia (N = 206) were treated with intramuscular (1-3 injections/24 hrs) olanzapine (2." | 5.10 | Calming versus sedative effects of intramuscular olanzapine in agitated patients. ( Alaka, K; Battaglia, J; Lindborg, SR; Meehan, K; Wright, P, 2003) |
| "This double-blind study investigated the efficacy and safety of rapid-acting intramuscular olanzapine in treating agitation associated with Alzheimer's disease and/or vascular dementia." | 5.10 | Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. ( Beasley, CM; Beckett, LM; Breier, A; David, SR; Feldman, PD; Jones, B; Meehan, KM; Mintzer, JE; Nisivoccia, JR; Wang, H, 2002) |
| "An intramuscular (IM) formulation of olanzapine has been developed because there are no rapid-acting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia." | 5.10 | A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. ( Birkett, M; Breier, A; Brook, S; David, S; Dossenbach, M; Ferchland, I; Kiesler, G; Meehan, K; Palmer, R; Sutton, V; Taylor, CC; Wright, P, 2002) |
| " This article compares the effects of olanzapine and placebo in the emergence of hallucinations or delusions in AD patients with symptoms of agitation/aggression but little or no psychotic symptomatology at baseline." | 5.09 | The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. ( Breier, A; Clark, WS; Feldman, PD; Street, JS, 2001) |
| "The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia." | 5.09 | Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. ( Alaka, KJ; Bernardo, M; Birkett, M; Bradley, P; Breier, A; David, SR; Ferchland, I; Krueger, J; Meehan, K; Reinstein, M; San, L; Saunders, JC; Wright, P, 2001) |
| "This first clinical study of olanzapine in Japanese patients with schizophrenia was conducted to investigate the efficacy and safety of olanzapine." | 5.09 | Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan. ( Ishigooka, J; Miura, S; Murasaki, M, 2001) |
| " ziprasidone and olanzapine for treating acute agitation in patients with schizophrenia are described, along with factors to consider when evaluating the cost-effectiveness of these agents." | 4.81 | Continuum of care: stabilizing the acutely agitated patient. ( Bellnier, TJ, 2002) |
| " This resistant case of lethal catatonia responded selectively to high-dose olanzapine treatment." | 3.71 | Lethal catatonia responding to high-dose olanzapine therapy. ( Cassidy, EM; Finucane, J; O'Brien, M; O'Keane, V; Osman, MF, 2001) |
| " A new approach to olanzapine dosing that expands the initial dose range up to 40 mg/d may offer superior efficacy in rapidly and effectively controlling the symptoms of agitation." | 2.71 | Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. ( Baker, RW; Hill, AL; Kinon, BJ; Liu, H; Maguire, GA, 2003) |
| "In olanzapine-treated patients, improvement in BPRS agitation and positive symptom scores was significantly greater at weeks 4, 5, and 6 (agitation scores, p < or = ." | 2.70 | Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. ( Hill, AL; Kinon, BJ; Milton, DR; Roychowdhury, SM, 2001) |
| " These findings suggest that intramuscular olanzapine is a safe and effective treatment for reducing acute agitation in patients with bipolar mania." | 2.70 | A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. ( Breier, A; David, S; Janicak, P; Koch, M; Meehan, K; Rizk, R; Small, J; Tohen, M; Tran, P; Walker, D; Zhang, F, 2001) |
| " Risk factors are a high dosage of antipsychotics, akathisia in a previous treatment, and diabetes mellitus." | 2.41 | [Drug-induced akathisia]. ( van Harten, PN, 2002) |
| "Olanzapine proved to be an adequate treatment choice for NIA patients." | 1.30 | Measuring neuroleptic-induced akathisia by three-channel actometry. ( Holi, M; Lauerma, H; Markkula, J; Rimon, R; Tuisku, K, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 20 (90.91) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellnier, TJ | 1 |
| Olson, DA | 1 |
| Ingram, W | 1 |
| Mann, JR | 1 |
| Hall, KL | 1 |
| Taylor, WH | 1 |
| Ware, MR | 1 |
| Daniel, DG | 1 |
| Battaglia, J | 1 |
| Lindborg, SR | 1 |
| Alaka, K | 1 |
| Meehan, K | 5 |
| Wright, P | 3 |
| Baker, RW | 1 |
| Kinon, BJ | 2 |
| Maguire, GA | 1 |
| Liu, H | 1 |
| Hill, AL | 2 |
| Landi, F | 1 |
| Cesari, M | 1 |
| Zuccalà, C | 1 |
| Barillaro, C | 1 |
| Cocchi, A | 1 |
| Buckley, PF | 1 |
| Tuisku, K | 1 |
| Lauerma, H | 1 |
| Holi, M | 1 |
| Markkula, J | 1 |
| Rimon, R | 1 |
| Feifel, D | 1 |
| Roychowdhury, SM | 1 |
| Milton, DR | 1 |
| Jones, B | 2 |
| Taylor, CC | 2 |
| Clark, WS | 1 |
| Street, JS | 1 |
| Feldman, PD | 2 |
| Breier, A | 5 |
| Birkett, M | 2 |
| David, SR | 2 |
| Ferchland, I | 2 |
| Alaka, KJ | 1 |
| Saunders, JC | 1 |
| Krueger, J | 1 |
| Bradley, P | 1 |
| San, L | 1 |
| Bernardo, M | 1 |
| Reinstein, M | 1 |
| Ishigooka, J | 1 |
| Murasaki, M | 1 |
| Miura, S | 1 |
| Zhang, F | 1 |
| David, S | 2 |
| Tohen, M | 1 |
| Janicak, P | 1 |
| Small, J | 1 |
| Koch, M | 1 |
| Rizk, R | 1 |
| Walker, D | 1 |
| Tran, P | 1 |
| Schneider, LS | 1 |
| Tariot, PN | 1 |
| Lyketsos, CG | 1 |
| Dagerman, KS | 1 |
| Davis, KL | 1 |
| Davis, S | 1 |
| Hsiao, JK | 1 |
| Jeste, DV | 1 |
| Katz, IR | 1 |
| Olin, JT | 1 |
| Pollock, BG | 1 |
| Rabins, PV | 1 |
| Rosenheck, RA | 1 |
| Small, GW | 1 |
| Lebowitz, B | 1 |
| Lieberman, JA | 1 |
| Cassidy, EM | 1 |
| O'Brien, M | 1 |
| Osman, MF | 1 |
| Finucane, J | 1 |
| O'Keane, V | 1 |
| van Harten, PN | 1 |
| Meehan, KM | 1 |
| Wang, H | 1 |
| Nisivoccia, JR | 1 |
| Beasley, CM | 1 |
| Mintzer, JE | 1 |
| Beckett, LM | 1 |
| Sutton, V | 1 |
| Palmer, R | 1 |
| Dossenbach, M | 1 |
| Kiesler, G | 1 |
| Brook, S | 1 |
| Sheikh, RM | 1 |
| Ahmed, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Individualized Music Playlist Based on ISO-Principle for De-escalating Agitation of People Living With Dementia: A Randomized Controlled Feasibility Study[NCT04236557] | 24 participants (Actual) | Interventional | 2022-11-01 | Completed | |||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)[NCT00015548] | 450 participants | Interventional | 2001-03-31 | Completed | |||
| An Open-label, Randomized Trial of Intramuscular (IM) Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia[NCT00797277] | Phase 3 | 67 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Agitation was further assessed by the Agitation Calmness Evaluation Scale (ACES) (Copyright 1998, Eli Lilly and Company), a single-item scale developed by Eli Lilly and Company on which 1 indicates marked agitation; 2, moderate agitation; 3, mild agitation; 4, normal; 5, mild calmness; 6, moderate calmness; 7, marked calmness; 8, deep sleep; and 9, unable to be aroused. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection
| Intervention | units on a scale (Mean) |
|---|---|
| 1. IM Olanzapine | 2.14 |
| 2. IM Haloperidol Pus Lorazepam | 2.23 |
The primary efficacy measure was PANSS-EC, which was derived from the PANSS by its originators using a principal-components factor analysis, and includes the items of tension, uncooperativeness, hostility, poor impulse control and excitement.22 The score of each item ranges from 1 (normal) to 7 (most severe), with a total sum score ranging from 5 to 35. The changes in PANSS-EC from baseline to 2 hours after the first injection were compared. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection
| Intervention | units on a scale (Mean) |
|---|---|
| 1. IM Olanzapine | -10.2 |
| 2. IM Haloperidol Plus Lorazepam | -9.9 |
5 reviews available for pirenzepine and Psychomotor Agitation
| Article | Year |
|---|---|
Continuum of care: stabilizing the acutely agitated patient.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Continuity of Patient Care; Cost-Be | 2002 |
Recent developments in pharmacotherapy for the acutely psychotic patient.
Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intr | 2002 |
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Loxapine; Mental Disorders; Ol | 1999 |
Rationale and guidelines for the inpatient treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Drug | 2000 |
[Drug-induced akathisia].
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Complications; D | 2002 |
11 trials available for pirenzepine and Psychomotor Agitation
| Article | Year |
|---|---|
Calming versus sedative effects of intramuscular olanzapine in agitated patients.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dementia; Doubl | 2003 |
Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-B | 2003 |
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Double- | 2001 |
The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric | 2001 |
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Delus | 2001 |
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, | 2001 |
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Benzodiazepines; Female; Humans; Japa | 2001 |
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania.
Topics: Adult; Affect; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Choline | 2001 |
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
Topics: Aged; Algorithms; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Citalopram; Cost-Benefit | 2001 |
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.
Topics: Acute Disease; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Dementia; Double-Bl | 2002 |
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relatio | 2002 |
6 other studies available for pirenzepine and Psychomotor Agitation
| Article | Year |
|---|---|
Combination of olanzapine and divalproex for agitation in individuals with profound mental retardation.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; H | 2002 |
Neuroleptic malignant syndrome due to olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Neuroleptic Malignant Syndrome; Olanza | 2001 |
Olanzapine and hypoglycemic coma in a frail elderly woman. A case report.
Topics: Aged; Aged, 80 and over; Benzodiazepines; Coma; Female; Humans; Hypoglycemia; Olanzapine; Pirenzepin | 2003 |
Measuring neuroleptic-induced akathisia by three-channel actometry.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Diagnos | 1999 |
Lethal catatonia responding to high-dose olanzapine therapy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Catatonia; Electroconvulsive Therapy | 2001 |
The efficacy of olanzapine, as needed, to treat acute agitation in juveniles.
Topics: Acute Disease; Age Factors; Antipsychotic Agents; Benzodiazepines; Child; Dose-Response Relationship | 2002 |